Treatment

Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response
Svetlana Cherlin, Myles J Lewis, Darren Plant, Nisha Nair, Katriona Goldmann, Evan Tzanis, Michael R Barnes, Paul McKeigue, Jennifer H Barrett, Costantino Pitzalis, Anne Barton, MATURA Consortium, Heather J Cordell

Annals of the Rheumatic Diseases Nov 2020, 79 (11) 1446-1452; DOI: 10.1136/annrheumdis-2020-217204
A pilot study of tofacitinib for refractory Behçet’s syndrome
Jinjing Liu, Yunxia Hou, Luxi Sun, Chaoran Li, Lu Li, Yan Zhao, Xiaofeng Zeng, Fengchun Zhang, Wenjie Zheng

Annals of the Rheumatic Diseases Nov 2020, 79 (11) 1517-1520; DOI: 10.1136/annrheumdis-2020-217307
Less antibiotics but no inferior effect for bacterial arthritis
Jian Tian, Chao Cheng, Fangjie Zhang

Annals of the Rheumatic Diseases Nov 2020, 79 (11) e144; DOI: 10.1136/annrheumdis-2019-215682
Is it currently reasonable to offer short, 14-day antibiotic therapies after a surgical synovectomy in native joint septic arthritis?
Guillaume Coiffier, Marion Couderc, Raphaele Seror, Geraldine Bart, Christelle Darrieutort-Laffite, Benoit Le Goff

Annals of the Rheumatic Diseases Nov 2020, 79 (11) e146; DOI: 10.1136/annrheumdis-2019-215887
Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter
Nabiha Sbeih, Alexis Mathian, Marc Pineton de Chambrun, Raphael Lhote, Noël Zahr, Micheline Pha, Fleur Cohen-Aubart, Julien Haroche, Miguel Hié, Sophie Jouffroy, Neila Benameur, Hervé Devilliers, Zahir Amoura

Annals of the Rheumatic Diseases Nov 2020, 79 (11) e148; DOI: 10.1136/annrheumdis-2019-215732
Response to: ‘Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter’ by Sbeih et al
Mandana Nikpour, Molla Huq, Shereen Oon

Annals of the Rheumatic Diseases Nov 2020, 79 (11) e149; DOI: 10.1136/annrheumdis-2019-215922
Response to: ‘Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations’ by Orsolini et al
Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas

Annals of the Rheumatic Diseases Nov 2020, 79 (11) e151; DOI: 10.1136/annrheumdis-2019-215944
Machine learning predicts stem cell transplant response in severe scleroderma
Jennifer M Franks, Viktor Martyanov, Yue Wang, Tammara A Wood, Ashley Pinckney, Leslie J Crofford, Lynette Keyes-Elstein, Daniel E Furst, Ellen Goldmuntz, Maureen D Mayes, Peter McSweeney, Richard A Nash, Keith M Sullivan, Michael L Whitfield

Annals of the Rheumatic Diseases Sep 2020, annrheumdis-2020-217033; DOI: 10.1136/annrheumdis-2020-217033
Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence
Bon San Koo, Ji Seon Oh, Seo Young Park, Ji Hui Shin, Ga Young Ahn, Seunghun Lee, Kyung Bin Joo, Tae-Hwan Kim

Annals of the Rheumatic Diseases Oct 2020, 79 (10) 1327-1332; DOI: 10.1136/annrheumdis-2019-216741
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
Hermine I Brunner, Carlos Abud-Mendoza, Diego O Viola, Inmaculada Calvo Penades, Deborah Levy, Jordi Anton, Julia E Calderon, Vyacheslav G Chasnyk, Manuel A Ferrandiz, Vladimir Keltsev, Maria E Paz Gastanaga, Michael Shishov, Alina Lucica Boteanu, Michael Henrickson, Damon Bass, Kenneth Clark, Anne Hammer, Beulah N Ji, Antonio Nino, David A Roth, Herbert Struemper, Mei-Lun Wang, Alberto Martini, Daniel Lovell, Nicolino Ruperto

Annals of the Rheumatic Diseases Oct 2020, 79 (10) 1340-1348; DOI: 10.1136/annrheumdis-2020-217101

Main menu

Treatment

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Treatment

Pages